


Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs
and Drug Control
MUSCAT



سلطنة عمان
وزارة الصحة
المديرية العامة للصيدل
والرقابة الدوائية
مسقط

Circular No. 64 / 2019

16 -08-1440 H

18 -12-2019

To

**ALL PRIVATE DRUG STORES &
LOCAL PHARMACEUTICAL MANUFACTURERS**

After Compliments,

Sub: Pharmaceutical products containing Angiotensin Receptor Blockers (ARBs)

This is to inform you that in the future applications for registration/re-registration of pharmaceutical products containing ARBs must include a declaration with supportive evidence from the API manufacturer that the manufacturing process of the API will not result in the presence of the carcinogenic impurities (NDMA and NDEA).

Yours faithfully

**Ph. Hussain Al Ramimmy
ACTG. DIRECTOR GENERAL**



Cc: DDC